Mutation profiles in circulating cell‐free <scp>DNA</scp> predict acquired resistance to olaparib in high‐grade serous ovarian carcinoma-Reference-Cited by-同舟云学术

Mutation profiles in circulating cell‐free DNA predict acquired resistance to olaparib in high‐grade serous ovarian carcinoma

Published:2022-06-26 Issue:8 Volume:113 Page:2849-2861
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Science

Author:

Hu Dianxing¹,Guo Ensong¹,Yang Bin¹,Qin Xu²,Fu Yu¹,Fan Junpeng¹^ORCID,Zhuang Xucui¹,Yao Qianqian³,Lu Funian¹,Li Wenting¹,Xiao Rourou¹,Wu Xue¹^ORCID,Yang Xiaohang¹,Wang Zizhuo¹,Liu Chen¹,You Lixin¹,Zang Rongyu⁴,Zhou Qi⁵,Zhao Weidong⁶,Chen Gang¹,Sun Chaoyang¹^ORCID

Affiliation:

1. Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology Wuhan China

2. Department of Stomatology, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology Wuhan China

3. Department of Medical Science Shanghai AccuraGen Biotechnology Co., Ltd. Shanghai China

4. Department of Gynecologic Oncology, Zhongshan Hospital Fudan University Shanghai China

5. Department of Gynecologic Oncology Chongqing University Cancer Hospital Chongqing China

6. Department of Gynecologic Oncology Anhui Provincial Cancer Hospital Hefei China

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.15456

Reference48 articles.

1. Epithelial ovarian cancer: Evolution of management in the era of precision medicine

2. PARP inhibitor resistance: the underlying mechanisms and clinical implications

3. Poly(ADP-ribose) polymerase inhibition: past, present and future

4. Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

5. PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical relevance of circulating tumor DNA in ovarian cancer: current issues and future opportunities;Exploration of Targeted Anti-tumor Therapy;2024-06-19

2. Epigenetic and Genomic Hallmarks of PARP-Inhibitor Resistance in Ovarian Cancer Patients;Genes;2024-06-07

3. Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window?;Cancer Treatment Reviews;2023-12

4. MRE11:p.K464R mutation mediates olaparib resistance by enhancing DNA damage repair in HGSOC;Cell & Bioscience;2023-09-27

5. Update on poly(ADP-ribose) polymerase inhibitors resistance in ovarian cancer;Frontiers in Pharmacology;2023-06-23